Sionna Therapeutics(SION.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Sionna Therapeutics
SION.US
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; and SION-719 and SION-451, which are nucleotide-binding domain 1 stabilizers in Phase 1 trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc.
1.944 T
SION.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Sionna Therapeutics to Present at J.P. Morgan Healthcare Conference

    Sionna Therapeutics Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 9:45 a.m. PT/12:45 p.m. ET. A live webcast will be available on the company’s Investor Relations website, with a replay accessible after the event. This announcement was generated by Public Technologies and is for informational purposes only.

    Reuters·
    US
    SION
    +1.46%
    Reuters·
    US
    SION
    +1.46%

    Sionna Therapeutics: NBD1-Targeted CFTR Stabilization Strategy Positions Pipeline for Best-in-Class Efficacy and Blockbuster Upside in Cystic Fibrosis

    Cory Jubinville, PhD, from LifeSci Capital, has initiated a Buy rating on Sionna Therapeutics, citing its innovative NBD1-targeted CFTR stabilization strategy for cystic fibrosis. This approach addresses the core defect in CF patients, offering potential best-in-class efficacy. Sionna's lead asset, SION-719, complements existing treatments, while other regimens provide diverse development opportunities. Jubinville highlights the commercial potential in a market dominated by Vertex, suggesting Sionna could capture significant share with improved efficacy or safety, supporting his positive outlook on the company's long-term value.

    Tip Ranks·
    US
    SION
    +1.46%
    Tip Ranks·
    US
    SION
    +1.46%

    Sionna Therapeutics (NASDAQ:SION) Director Sells $38,928.75 in Stock

    Sionna Therapeutics Director Orbimed Advisors LLC sold 875 shares for $38,928.75, reducing their ownership by 0.02%. The sale was disclosed in an SEC filing. The stock price fell 4.2% to $42.37. Analysts have mixed ratings on the stock, with a consensus rating of 'Moderate Buy' and a price target of $40.33. Sionna Therapeutics is a biotech company focused on RNA therapeutics for oncology and immunology.

    Market Beat·
    US
    SION
    +1.46%
    Market Beat·
    US
    SION
    +1.46%

    OrbiMed Advisors LLC Reports Sale of Sionna Therapeutics Common Shares

    OrbiMed Advisors LLC has reported the sale of common shares of Sionna Therapeutics Inc. (SION) as per a recent SEC Form 4 filing. The filing was made by multiple reporting persons, including OrbiMed Advisors LLC and other beneficial owners. This information was published by Sionna Therapeutics Inc. via the SEC's EDGAR system.

    Reuters·
    US
    SION
    +1.46%
    Reuters·
    US
    SION
    +1.46%

    Director Peter A. Thompson Reports Disposal of Sionna Therapeutics Inc. Common Shares

    Peter A. Thompson, a Director of Sionna Therapeutics Inc., has reported the disposal of common shares of the company. This information was published via EDGAR by the U.S. Securities and Exchange Commission on December 19, 2025.

    Reuters·
    US
    SION
    +1.46%
    Reuters·
    US
    SION
    +1.46%
    © 2026 Longbridge｜Disclaimer